Neurology Trial: 36 week study phase 2 study to assess the effect of drug on functional decline in subjects with ALS

INCLUSION:

• Male/ Female 18-75 years of age
• Clinically definite, laboratory probable, or clinically probable ALS
• ALS symptom onset < 2 years prior to screening visit
• Subjects on riluzole may enter the study if they have been on a stable dose of 50mg BID for >4 weeks prior to screening visit.

EXCLUSION:

• Subject has participated in any previous ALS drug study unless at least 5 half lifes have passed since last dose and screening visit
• Subject has participated in any non-ALS therapeutic (drug or device) trial in the 4 weeks prior to screening visit.